Skip to content

Glucagon Efficiency After High and Low Carbohydrate Diet

Glucagon Efficiency After High and Low Carbohydrate Diet

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02578498
Acronym
HiLoCarb
Enrollment
10
Registered
2015-10-19
Start date
2015-10-31
Completion date
2016-07-31
Last updated
2016-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoglycemia, Type 1 Diabetes

Keywords

glucagon, Carbohydrate diet

Brief summary

No studies have investigated if the dietary composition of carbohydrate influences the glycaemic effect of single and multiple boluses of subcutaneous low-dose glucagon. Further, the recommended diet composition to patients with type 1 diabetes has not been thoroughly validated. Many patients with type 1 diabetes practice low carbohydrate eating patterns due to the assumption that this diet can reduce fluctuations in plasma glucose. Before glucagon can be used as an add-on to intensive insulin treatment, these aspects need to be elucidated. The purpose of this study is to determine, whether diet composition of carbohydrate affects the glycogen stores in the liver and affects the glucose response of glucagon during hypoglycaemia. HYPOTHESIS: In patients with type 1 diabetes, the glucose response of a single bolus of low-dose glucagon is not associated with diet carbohydrate content. AIM: The aim is to investigate how one week of high- compared to low-carbohydrate diet influence the glycaemic response of low-dose glucagon in patients with insulin pump treated type 1 diabetes. The secondary aim is to investigate how two dietary intervention weeks differ in the incidence of hypoglycaemia, postprandial hyperglycaemia, and daily glucose excursions. DESIGN:A non-blinded two-way cross-over, randomized study will be conducted. After participants have given an informed consent, they will go through four steps: 1) screening visit 2) Run-in period, 3) first meal intervention for one week finalizing with one study visit and 4) second meal intervention for one week finalizing with another study visit.

Interventions

DIETARY_SUPPLEMENTHigh carbohydrate intake

Carbohydrate intake \< 50 gram

DIETARY_SUPPLEMENTLow carbohydrate intake

Carbohydrate intake \> 250 gram

Sponsors

Danish Diabetes Academy
CollaboratorOTHER
Hvidovre University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Age 18 - 70 years * T1D ≥ 3 year * BMI 20-27 kg/m2 * CSII ≥ 1 year * HbA1c \< 69 mmol/mol (8.5 %) * C-peptide negative (\< 60 pmol/l) * Hypoglycemia awareness (self-reported) * Use of carbohydrate counting and the insulin pump bolus calculator for all meals

Exclusion criteria

* Allergy or intolerance to lactose or Glucagen®(Novo Nordisk, Bagsværd, DK) * Impaired renal function (eGFR \< 60 ml/min/1.73m2) * Liver disease with ALAT \> 2.5 times the upper limit of the reference interval * Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start * Known or suspected alcohol or drug abuse * Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation * Females who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods. * Inability to understand the patient information and to give informed consent.

Design outcomes

Primary

MeasureTime frame
Incremental area under the glucose curve0-240 minutes
Peak glucose valuewithin 240 minutes

Secondary

MeasureTime frameDescription
Triglycerides concentration0-240 min.Blood samples
Katekolamine concentration0-240 min.Blood samples
Ketone bodies concentration0-240 min.Blood samples
Free fatty acids concentration0-240 min.
Glucagon concentration0-240 min.Blood samples
Headache0-240 min.Visual analog scale
Hypoglycemia symptoms0-240 min.Visual analog scale
Vomit0-240 min.Occurence
Plasma glucose variationTwo weeksA continuous glucose monitor register daily glucose variation levels for two weeks.
Nausea0-240 min.Visual analog scale
Insulin concentration0-240 min.Blood samples

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026